SymBiosis is a biotechnology venture capital firm located in Arkansas. The company invests in bioengineering innovators who are developing advanced therapeutic platforms aimed at treating life-threatening diseases. SymBiosis Capital Management envisions a future where biology can be engineered at an industrial scale, making advanced medicines more accessible.
The firm focuses on companies that are working on advanced or emerging therapeutic platforms, including novel biologics, cell therapies, and gene therapies. They prioritize innovations that address serious health conditions such as cardiovascular, infectious, neurologic, and oncologic diseases. SymBiosis supports its partners from pre-IND stages through commercialization, emphasizing the importance of manufacturability and clinical validation in the development process.
Detailed Information
Fields marked — are added by the business owner once they claim this listing.